Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Total Liabilities (2020 - 2024)

Immuneering has reported Total Liabilities over the past 5 years, most recently at $10.8 million for Q3 2024.

  • Quarterly results put Total Liabilities at $10.8 million for Q3 2024, up 9.86% from a year ago — trailing twelve months through Sep 2024 was $10.8 million (up 9.86% YoY), and the annual figure for FY2023 was $12.0 million, down 4.06%.
  • Total Liabilities for Q3 2024 was $10.8 million at Immuneering, up from $10.8 million in the prior quarter.
  • Over the last five years, Total Liabilities for IMRX hit a ceiling of $28.5 million in Q1 2021 and a floor of $2.8 million in Q4 2020.
  • Median Total Liabilities over the past 5 years was $10.3 million (2021), compared with a mean of $10.9 million.
  • Biggest five-year swings in Total Liabilities: soared 282.94% in 2021 and later crashed 70.59% in 2022.
  • Immuneering's Total Liabilities stood at $2.8 million in 2020, then soared by 282.94% to $10.7 million in 2021, then rose by 16.71% to $12.5 million in 2022, then fell by 4.06% to $12.0 million in 2023, then dropped by 9.76% to $10.8 million in 2024.
  • The last three reported values for Total Liabilities were $10.8 million (Q3 2024), $10.8 million (Q2 2024), and $9.3 million (Q1 2024) per Business Quant data.